These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26909483)

  • 1. Incidence of vertebral fractures in calcium and vitamin D-supplemented postmenopausal Brazilian women with osteopenia or osteoporosis: data from Arzoxifene Generations Trial.
    Arantes HP; Gimeno SG; Chiang AY; Bilezikian JP; Lazaretti-Castro M
    Arch Endocrinol Metab; 2016 Feb; 60(1):54-9. PubMed ID: 26909483
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial.
    Kanis JA; Johnell O; Black DM; Downs RW; Sarkar S; Fuerst T; Secrest RJ; Pavo I
    Bone; 2003 Sep; 33(3):293-300. PubMed ID: 13678769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.
    Silverman SL; Delmas PD; Kulkarni PM; Stock JL; Wong M; Plouffe L
    J Am Geriatr Soc; 2004 Sep; 52(9):1543-8. PubMed ID: 15341559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
    JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
    Ettinger B; Black DM; Mitlak BH; Knickerbocker RK; Nickelsen T; Genant HK; Christiansen C; Delmas PD; Zanchetta JR; Stakkestad J; Glüer CC; Krueger K; Cohen FJ; Eckert S; Ensrud KE; Avioli LV; Lips P; Cummings SR
    JAMA; 1999 Aug; 282(7):637-45. PubMed ID: 10517716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
    Cummings SR; McClung M; Reginster JY; Cox D; Mitlak B; Stock J; Amewou-Atisso M; Powles T; Miller P; Zanchetta J; Christiansen C
    J Bone Miner Res; 2011 Feb; 26(2):397-404. PubMed ID: 20658564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM; Hillner BE
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
    Powles TJ; Diem SJ; Fabian CJ; Neven P; Wickerham DL; Cox DA; Muram D; Agnusdei D; Dowsett SA; Amewou-Atisso M; Cummings SR
    Breast Cancer Res Treat; 2012 Jul; 134(1):299-306. PubMed ID: 22484799
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia.
    Seeman E; Devogelaer JP; Lorenc R; Spector T; Brixen K; Balogh A; Stucki G; Reginster JY
    J Bone Miner Res; 2008 Mar; 23(3):433-8. PubMed ID: 17997711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of osteoporosis and vertebral fractures in postmenopausal women with type 2 diabetes mellitus and their relationship with duration of the disease and chronic complications.
    Viégas M; Costa C; Lopes A; Griz L; Medeiro MA; Bandeira F
    J Diabetes Complications; 2011; 25(4):216-21. PubMed ID: 21458300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incident Fracture Risk in Type 2 Diabetic Postmenopausal Women in Mainland China: Peking Vertebral Fracture Study.
    Jiajue R; Qi X; Jiang Y; Wang Q; Wang W; Pei Y; Wang X; Huang W; Zheng X; Ning Z; Wang O; Li M; Xing X; Yu W; Xu L; Xia W
    Calcif Tissue Int; 2019 Nov; 105(5):466-475. PubMed ID: 31511960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk.
    Boonen S; Adachi JD; Man Z; Cummings SR; Lippuner K; Törring O; Gallagher JC; Farrerons J; Wang A; Franchimont N; San Martin J; Grauer A; McClung M
    J Clin Endocrinol Metab; 2011 Jun; 96(6):1727-36. PubMed ID: 21411557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
    Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin D and vitamin D analogues for preventing fractures in post-menopausal women and older men.
    Avenell A; Mak JC; O'Connell D
    Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD000227. PubMed ID: 24729336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.
    McCloskey E; Selby P; Davies M; Robinson J; Francis RM; Adams J; Kayan K; Beneton M; Jalava T; Pylkkänen L; Kenraali J; Aropuu S; Kanis JA
    J Bone Miner Res; 2004 May; 19(5):728-36. PubMed ID: 15068495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.